Glutathione (GSH) In The Treatment of Parkinson's Disease

Completed · Phase 2

Conditions studied: Parkinson's Disease

In brief

This is an investigator initiated pilot study to examine the effects of GSH in PD. The goal of this study is to acquire some basic data regarding side effects and efficacy of this compound to determine if this is a possible treatment option that could be recommended to interested PD patients.

Key facts

Study ID

NCT01177319

Run by

University of South Florida

People needed

20

Starts

2003-09-01

Expected to finish

2007-03-01

Last updated by the study team

2010-08-09

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Idiopathic Parkinson's disease (2 of 3 of the cardinal symptoms:tremor, bradykinesia, rigidity)
• Mini Mental State Examination > 24
• Anti-parkinsonian medications stable for one month
• Hoehn and Yahr II-IV
• Age 18 and above

You may not qualify if…

• Atypical parkinsonism
• History of seizure, drug addiction
• Use of typical neuroleptics
• Previous use of glutathione

Where it is running

• USF Parkinson's Disease and Movement Disorders Center — Tampa, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.